trending Market Intelligence /marketintelligence/en/news-insights/trending/id_lfps7acexjvttkhuzxg2 content esgSubNav
In This List

Sun Pharmaceutical skin drug bags US FDA approval

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Sun Pharmaceutical skin drug bags US FDA approval

India's Sun Pharmaceutical Industries Ltd. secured the U.S. Food and Drug Administration's approval to market Ilumya as a treatment for moderate-to-severe plaque psoriasis.

Plaque psoriasis is a skin disease that causes red, painful and itchy patches with a silvery white buildup of dead skin cells or scale.

The company's regulatory filing was backed by the results of two phase 3 clinical trials that demonstrated the treatment was better at improving skin clearance than placebo.